Incremental Value of Systematic Biopsy in Patients with Prostate Imaging Reporting and Data System 5 Lesions Undergoing MRI–Ultrasound Fusion Biopsy: A Single-Operator Study in a Secondary-Care Setting
Diagnostics · 2026-11-12 · 16 (22) · 3736
DOI: 10.3390/diagnostics16223736 ↗Abstract
Background/Objectives: This study aimed to evaluate the incremental value of systematic biopsy (SB) in addition to targeted biopsy (TB) and its impact on Grade Group (GG) reclassification in patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions. Methods: We retrospectively reviewed data from 32 patients with PI-RADS 5-only lesions who underwent magnetic resonance imaging–ultrasound fusion transrectal biopsy by a single operator. Based on the patient-level maximum GG, we evaluated the detection of any prostate cancer (GG ≥ 1), clinically significant prostate cancer (GG ≥ 2), and high-grade prostate cancer (GG ≥ 3). An exploratory subgroup analysis was performed according to prostate-specific antigen density (PSAD;
EUVIMED